The H2 receptor antagonist marketis poised for significant growth in the coming years, fueled by several key factors shaping the industry landscape. The rising prevalence of gastrointestinal disorders, including GERD, peptic ulcers, and gastritis, is driving the demand for H2 receptor antagonists as first-line treatment options.
